Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting

Familial Cancer

Volumn 8, Issue 4, 2009, Pages 277-287

  Morgan, Debra ^a   Sylvester, Heather ^b   Lucas, F Lee ^c   Miesfeldt, Susan ^a,b  

^a Maine Medical Center Research Institute   (United States)

^b Maine Center for Cancer Medicine and Blood Disorders   (United States)

^c MAINE MEDICAL CENTER   (United States)

Author keywords

Adherence; Genetic counseling; Hereditary breast and ovarian cancer; Prevention; Risk assessment; Risk reducing surgery; Screening

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; TAMOXIFEN;

ADULT; AGED; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER SCREENING; COMMUNITY PROGRAM; FAMILIAL CANCER; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; HEALTH SURVEY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT ATTITUDE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CA-125 ANTIGEN; ENDOSONOGRAPHY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 70449519309     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9242-z     Document Type: Article

References (44)

1. HT Lynch CL Snyder, et al. 2003 Hereditary breast ovarian cancer at the bedside: role of the medical oncologist J Clin Oncol 21 4 740 753 10.1200/JCO.2003.05.096 10.1200/JCO.2003.05.096 12586815 (Pubitemid 46621912)
2. SA Narod WD Foulkes 2004 BRCA1 and BRCA2: 1994 and beyond Nat Rev Cancer 4 9 665 676 10.1038/nrc1431 10.1038/nrc1431 1:CAS:528:DC%2BD2cXntFCmsbk%3D 15343273 (Pubitemid 39215065)
3. D Ford DF Easton, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am J Hum Genet 62 3 676 689 10.1086/301749 10.1086/301749 1:CAS:528:DyaK1MXlvFeh 9497246 (Pubitemid 28164626)
4. A Antoniou PD Pharoah, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 5 1117 1130 10.1086/375033 10.1086/375033 1:CAS:528:DC%2BD3sXjslagtbg%3D 12677558 (Pubitemid 36530000)
5. DF Easton L Steele, et al. 1997 Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13 Am J Hum Genet 61 1 120 128 10.1086/513891 10.1086/513891 1:STN:280:DyaK2szovVOmuw%3D%3D 9245992
6. JP Struewing P Hartge, et al. 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 20 1401 1408 10.1056/NEJM199705153362001 10.1056/NEJM199705153362001 1:STN:280:DyaK2s3nsVShug%3D%3D 9145676 (Pubitemid 27208598)
7. The Breast Cancer Linkage Consortium 1999 Cancer risks in BRCA2 mutation carriers J Natl Cancer Inst 91 15 1310 1316 10.1093/jnci/91.15.1310 10.1093/jnci/91.15.1310
8. MS Brose TR Rebbeck, et al. 2002 Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program J Natl Cancer Inst 94 18 1365 1372 1:CAS:528:DC%2BD38Xnt1Gnurg%3D 12237282
9. D Thompson DF Easton 2002 Cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst 94 18 1358 1365 1:CAS:528:DC%2BD38Xnt1Gnurs%3D 12237281 (Pubitemid 35154140)
10. S Chen G Parmigiani 2007 Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 11 1329 1333 10.1200/JCO.2006.09.1066 10.1200/JCO.2006.09.1066 17416853 (Pubitemid 46706879)
11. U.S. Preventive Services Task Force 2005 Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement Ann Intern Med 143 5 355 361
12. ND Kauff SM Domchek, et al. 2008 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study J Clin Oncol 26 8 1331 1337 10.1200/JCO.2007.13. 9626 10.1200/JCO.2007.13.9626 18268356
13. LJ Herrinton WE Barlow, et al. 2005 Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project J Clin Oncol 23 19 4275 4286 10.1200/JCO.2005.10.080 10.1200/JCO.2005.10.080 15795415 (Pubitemid 46207002)
14. SM Domchek TM Friebel, et al. 2006 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study Lancet Oncol 7 3 223 229 10.1016/S1470-2045(06)70585-X 10.1016/S1470-2045(06)70585-X 1:CAS:528:DC%2BD28XitVeitLs%3D 16510331 (Pubitemid 43286452)
15. J Gronwald N Tung, et al. 2006 Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update Int J Cancer 118 9 2281 2284 10.1002/ijc.21536 10.1002/ijc.21536 1:CAS:528:DC%2BD28XjsVCgt7Y%3D 16331614
16. M Epplein KP Koon, et al. 2005 Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers J Clin Oncol 23 21 4713 4718 10.1200/JCO.2005.00.133 10.1200/JCO.2005.00.133 16034046 (Pubitemid 46224074)
17. LC Friedman HP Cooper, et al. 2003 Primary care physicians' attitudes and practices regarding cancer genetics: a comparison of 2001 with 1996 survey results J Cancer Educ 18 2 91 94 10.1207/S15430154JCE1802-11 10.1207/S15430154JCE1802-11 12888383
18. L Wideroff AN Freedman, et al. 2003 Physician use of genetic testing for cancer susceptibility: results of a national survey Cancer Epidemiol Biomarkers Prev 12 4 295 303 12692103 (Pubitemid 36427989)
19. ST Tinley J Houfek, et al. 2004 Screening adherence in BRCA1/2 families is associated with primary physicians' behavior Am J Med Genet 125 1 5 11 10.1002/ajmg.a.20431 10.1002/ajmg.a.20431
20. C Lerman C Hughes, et al. 2000 Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing Prev Med 31 1 75 80 10.1006/pmed.2000.0684 10.1006/pmed.2000.0684 1:STN:280:DC%2BD3cvit1GnsA%3D%3D 10896846 (Pubitemid 30471180)
21. JR Botkin KR Smith, et al. 2003 Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing Am J Med Genet 118 3 201 209 10.1002/ajmg.a.10102 10.1002/ajmg.a.10102
22. H Meijers-Heijboer CT Brekelmans, et al. 2003 Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation J Clin Oncol 21 9 1675 1681 10.1200/JCO.2003.09.052 10.1200/JCO.2003.09.052 12721241 (Pubitemid 46638577)
23. BN Peshkin MD Schwartz, et al. 2002 Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing Cancer Epidemiol Biomarkers Prev 11 10 Pt 1 1115 1118 12376518
24. L Scheuer N Kauff, et al. 2002 Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers J Clin Oncol 20 5 1260 1268 10.1200/JCO.20.5.1260 10.1200/JCO.20.5.1260 11870168 (Pubitemid 34177432)
25. C Isaacs BN Peshkin, et al. 2002 Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer Breast Cancer Res Treat 71 2 103 112 10.1023/A:1013800409238 10.1023/A:1013800409238 11881908 (Pubitemid 34145368)
26. KA Metcalfe J Jan Lubinski, et al. 2008 Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the hereditary breast cancer clinical study group J Clin Oncol 26 7 1093 1097 10.1200/JCO.2007.12.6078 10.1200/JCO.2007.12.6078 18195327
27. CH Barcenas GM Hosain, et al. 2006 Assessing BRCA carrier probabilities in extended families J Clin Oncol 24 3 354 360 10.1200/JCO.2005.02.2368 10.1200/JCO.2005.02.2368 16421416 (Pubitemid 46630453)
28. PA James R Doherty, et al. 2006 Optimal selection of individuals for BRCA mutation testing: a comparison of available methods J Clin Oncol 24 4 707 715 10.1200/JCO.2005.01.9737 10.1200/JCO.2005.01.9737 1:CAS:528:DC%2BD28XhvFKhtb4%3D 16446345 (Pubitemid 46630438)
29. W Burke M Daly J Garber, et al. 1997 Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium JAMA 277 12 997 1003 10.1001/jama.277.12.997 10.1001/jama.277.12.997 1:STN:280:DyaK2s3ivVSguw%3D%3D 9091675 (Pubitemid 27142370)
30. NCCN Breast Cancer Panel (2000) NCCN practice guidelines for genetics/familial high-risk screening. Breast, Version 1
31. S Tinley, et al. 2004 Screening adherence in BRCA 1/2 families is associated with primary physicians' behavior Am J Med Genet 125A 1 5 11 10.1002/ajmg.a.20431 10.1002/ajmg.a.20431 14755459
32. R Wooster BL Weber 2003 Breast and ovarian cancer N Engl J Med 348 23 2339 2347 10.1056/NEJMra012284 10.1056/NEJMra012284 1:CAS:528: DC%2BD3sXkt1Kktrc%3D 12788999 (Pubitemid 36638109)
33. MR McClain GE Palomaki, et al. 2005 Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications Genet Med 7 1 28 33 10.1097/01.GIM.0000151155.36470.FF 1:CAS:528:DC%2BD2MXkvFWgug%3D%3D 15654225 (Pubitemid 40111128)
34. C Lerman S Narod, et al. 1996 BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes JAMA 275 24 1885 1892 10.1001/jama.275.24.1885 10.1001/jama.275.24.1885 1:STN:280:DyaK283ls1ensA%3D%3D 8648868 (Pubitemid 26196448)
35. LC Hartmann TA Sellers, et al. 2001 Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers J Natl Cancer Inst 93 21 1633 1637 1:CAS:528:DC%2BD3MXptVegt7g%3D 11698567
36. ND Kauff JM Satagopan, et al. 2002 Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 21 1609 1615 10.1056/NEJMoa020119 10.1056/NEJMoa020119 12023992 (Pubitemid 34755668)
37. MC King S Wieand, et al. 2001 Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial JAMA 286 18 2251 2256 10.1001/jama.286.18.2251 10.1001/jama.286.18.2251 1:CAS:528: DC%2BD3MXosFCktr8%3D 11710890
38. K Armstrong DA Quistberg, et al. 2006 Prescription of tamoxifen for breast cancer prevention by primary care physicians Arch Intern Med 166 20 2260 2265 10.1001/archinte.166.20.2260 10.1001/archinte.166.20.2260 17101945 (Pubitemid 44748773)
39. R Taylor K Taguchi 2005 Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump Ann Fam Med 3 3 242 247 10.1370/afm.284 10.1370/afm.284 15928228 (Pubitemid 40806718)
40. MJ Stoutjesdijk C Boetes, et al. 2001 Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer J Natl Cancer Inst 93 14 1095 1102 10.1093/jnci/93.14.1095 10.1093/jnci/93.14.1095 1:STN:280:DC%2BD3MvisVamuw%3D%3D 11459871
41. M Kriege CT Brekelman, et al. 2004 Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition N Engl J Med 351 5 427 437 10.1056/NEJMoa031759 10.1056/NEJMoa031759 1:CAS:528:DC%2BD2cXmtFalu7o%3D 15282350 (Pubitemid 38988592)
42. MO Leach CR Boggis, et al. 2005 Screening with magnetic resonance imaging and mammography in a UK population at high familial risk of breast cancer : a prospective multicentre cohort study (MARIBS) Lancet 365 9473 1769 1778 10.1016/S0140-6736(05)66481-1 10.1016/S0140-6736(05)66481-1 1:STN:280: DC%2BD2M3mvFCqtg%3D%3D 15910949 (Pubitemid 40744657)
43. E Warner DB Plewes, et al. 2004 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292 1317 1325 10.1001/jama.292.11.1317 10.1001/jama.292.11.1317 1:CAS:528:DC%2BD2cXns12rs78%3D 15367553 (Pubitemid 39223222)
44. D Saslow, et al. 2007 American cancer society guidelines breast screening with MRI as an adjunct to mammography CA Cancer J Clin 57 75 89 10.3322/canjclin.57.2.75 17392385 (Pubitemid 46535708)